Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
06/2003
06/03/2003US6573264 Heteroaryl alkyl piperazine derivatives
06/03/2003US6573259 Inhibitors of interleukin-1β converting enzyme
06/03/2003US6573255 Vitamin D analogues
06/03/2003US6573239 Compound comprising 15 to 26-residue peptide or peptide analogue which forms amphipathic alpha-helix in presence of lipids and exhibits specified lecithin:cholesterol acyltransferase activation activity
06/03/2003US6573096 Continuous cell lines which produce monospecific antibodies that specifically bind an epitope of a human dipeptidyl peptidase IV and thereby inhibit angiogenesis; use in treatment of cancer
06/03/2003US6573095 Polynucleotides isolated from skin cells
06/03/2003US6573066 FtsH from Staphylococcus aureus
06/03/2003US6572895 Treatment of congestive heart failure
06/03/2003US6572876 Soy protein, isoflavone and plant sterol coadministered for atherosclerosis prevention
06/03/2003US6572873 Sclerosing liquid for blood vessels, varicose veins and other disorders involving venous malformation; injectable foam using high volume percentages of blood dispersible gases, thus avoiding use of potentially hazardous amounts of nitrogen
06/03/2003US6572852 Genetic engineering
06/03/2003CA2413491A1 Treatment for ischemic stroke
06/03/2003CA2223625C Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
06/03/2003CA2047858C (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
05/2003
05/30/2003WO2003044524A2 Methods and means for influencing intracellular communication and intracellular organelle transport
05/30/2003WO2003044172A2 Composition comprising and method of using angiopoietin-like protein 3 angptl3
05/30/2003WO2003044170A2 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
05/30/2003WO2003044162A2 Genes encoding g-protein coupled receptors and methods of use therefor
05/30/2003WO2003044053A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/30/2003WO2003044044A1 Novel peptide having angiotensin convertase inhibitory effect
05/30/2003WO2003044023A1 The use of anti-histaminics for acute reduction of elevated intracranial pressure
05/30/2003WO2003044021A2 Substituted indolizine-like compounds and methods of use
05/30/2003WO2003044014A1 Indole-2-carboxamides as factor xa inhibitors
05/30/2003WO2003044010A1 Nitrogenous tetrahydropyridyl-alkyl-heterocycles with tnf activity
05/30/2003WO2003044009A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/30/2003WO2003044006A1 Substituted benzopyrans as selective estrogen receptor-beta agonists
05/30/2003WO2003044000A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/30/2003WO2003043999A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/30/2003WO2003043992A1 4-oxoquinoline derivatives
05/30/2003WO2003043988A1 Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient
05/30/2003WO2003043987A2 (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
05/30/2003WO2003043985A1 Heterocyclic compounds and methods of use
05/30/2003WO2003043981A1 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors
05/30/2003WO2003043656A1 Drug for preventing vascular restenosis and instrument to be embedded in vessel coated with the drug
05/30/2003WO2003043651A1 Drug mobilizing pluripotent stem cells from tissue into peripheral blood
05/30/2003WO2003043645A1 Compositions comprising organic extracts of geum japonicum thunb var. and the use thereof
05/30/2003WO2003043639A2 PHARMACEUTICAL COMPOSITION COMPRISING A ClC-2 CHANNEL OPENER
05/30/2003WO2003043636A1 Nicotin-or isonicotin benzothiazole derivatives
05/30/2003WO2003043635A1 Amlodipine salt forms and processes for preparing them
05/30/2003WO2003043634A1 Benzothiazole derivatives as adenosine receptor ligands
05/30/2003WO2003043625A1 2-aryl-propionic acids and pharmaceutical compositions containing them
05/30/2003WO2003043615A2 Hypertonia treatment during the acute phase of a cerebrovascular accident
05/30/2003WO2003043613A2 Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents
05/30/2003WO2003043612A1 Micronized film-forming powder comprising an active substance
05/30/2003WO2003008448A3 Novel human proton-gated channels
05/30/2003WO2003005998A3 A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent of modulating cholinergic function
05/30/2003WO2003004006A3 Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
05/30/2003WO2003002106A3 Use of tyrosine kinase inhibitions for treating allergic diseases
05/30/2003WO2002102360A3 Compositions based on branched chain amino acids for improving the myocardial ventricular function in patients suffering from diabetes
05/30/2003WO2002100328A3 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
05/30/2003WO2002096363A3 Method for treating fibrotic diseases or other indications
05/30/2003WO2002088100A3 Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
05/30/2003WO2002078718A3 Compositions, methods and apparatuses for singlet oxygen delivery
05/30/2003WO2002070509A3 Antagonists of mcp-1 function and methods of use thereof
05/30/2003WO2002064621A3 Histidine proline rich glycoprotein (hprg) as an anti-angiogenic and anti-tumor agent
05/30/2003WO2002062795A3 Dihydropyrazolopyridine compounds and pharmaceutical use thereof
05/30/2003WO2002041827A9 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
05/30/2003WO2002036148A3 Use of death receptor ligands or rip to initiate the non-caspase-dependent cell death and compounds for inhibition of the non-caspase-dependent cell death
05/30/2003CA2468018A1 Micronized film-forming powder comprising an active substance
05/30/2003CA2467752A1 Piperidin-2-one derivative compounds and pharmaceutical composition comprising the same as active ingredient
05/30/2003CA2467749A1 (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
05/30/2003CA2467557A1 Agent which mobilizes multipotential stem cells from tissues to peripheral blood
05/30/2003CA2467551A1 Benzothiazole derivatives as adenosine receptor ligands
05/30/2003CA2467206A1 Genes encoding g-protein coupled receptors and methods of use therefor
05/30/2003CA2467095A1 Hypertonia treatment during the acute phase of a cerebrovascular accident
05/30/2003CA2467053A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/30/2003CA2466733A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/30/2003CA2466491A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/30/2003CA2466072A1 Substituted indolizine-like compounds and methods of use
05/30/2003CA2464542A1 Composition comprising and method of using angiopoietin-like protein 3 angptl3
05/30/2003CA2463790A1 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
05/29/2003US20030100942 Hydrogel for the therapeutic treatment of aneurysms
05/29/2003US20030100770 D-proline derivatives
05/29/2003US20030100769 Such s 2-(6-chloro-3-pyridyl)-2-imidazoline which has good affinity for and activate alpha-4-beta-2-nicotinic acetyl-choline receptors; for treatment and prevention of neuro-degenerative disorders (Alzheimer's/Parkinson's disease)
05/29/2003US20030100616 Administering to a patient for the treatment and/or prophylaxis an effective amount of 3-amino-propoxy derivative as a potent, beta-1-sepcific beta blocker whith a short duration of action in the systemic circulation
05/29/2003US20030100610 Omega -3 series polyunsaturated fatty acids are selected from eicosapentanoic acid and/or docosahexaenoic acid and/or pharmaceutically acceptable derivative
05/29/2003US20030100608 1,4-disubstituted benzo-fused cycloalkyl urea compounds
05/29/2003US20030100607 Thiolalkyl benzoic acid derivatives
05/29/2003US20030100603 Administering to the patient subject to a C-reactive protein associated inflammatory condition, an effective amount of a non-alpha-tocopherol enriched tocopherol
05/29/2003US20030100600 Method for treating atherosclerosis or restenosis using microtubule stabilizing agent
05/29/2003US20030100594 Carbonic anhydrase inhibitor
05/29/2003US20030100588 Indole-type inhibitors of p38 kinase
05/29/2003US20030100587 New substituted 2,4-thiazolidinedione derivatives, processes for producing them and pharmaceutical compositions containing them
05/29/2003US20030100585 For example 3-(2-(1-(2-(3-Methoxy-4-(3-o-tolyl-ureido)-phenyl)-acetylamino )- 3-methyl-butyl)-4,5-dihydro-oxazol-5-yl)-2-methyl-propionic acid
05/29/2003US20030100577 Neurotrophic agents in treatment of solid tumors and vascular disease
05/29/2003US20030100571 Such as 2-((6-(((4-(3,4-dimethoxyphenyl)methyl)amino)-7-ethyl-7H-purin-2-yl)amino) -4,5-methyl-N-phenyl-5-thiazole-carboxamide for treatment of lymphocyte mediated diseases such as transplant rejection and graft versus host disease
05/29/2003US20030100570 Immunomodulation and effect on cell processes relating to serotonin family receptors
05/29/2003US20030100567 Tyrosine kinase inhibitors
05/29/2003US20030100566 Sustained release ranolazine formulations
05/29/2003US20030100564 Administering 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione and/or metabolite thereof; treating neoplastic diseases, atherosclerosis, restenosis, rheumatoid arthritis, Crohn's disease, diabetic retinopathy, psoriasis, and endometriosis
05/29/2003US20030100563 Such as 7-((3R)-3-amino-4-(3,4-difluorophenyl)butanoyl)-2-(trifluoromethyl)-5,6,7,8 -tetrahydroimidazo(1,2-a)pyrazine dihydrochloride for treatment of insulin resistance disorders
05/29/2003US20030100561 Treatment of insulin resistance with growth hormone secretagogues
05/29/2003US20030100558 Such as 4-(4-fluorophenyl)-5-(2-phenylmethylamino)pyrimidin-4-yl)-1-ethoxymethyl -(1,2,3)triazole for inhibition of release of inflammatory interleukins; for treatment of osteoarthritis, rheumatoid arthritis, and congestive heart failure
05/29/2003US20030100556 Such as (S)-N-(5-(4-Methylpiperazin-1-yl)-3,4-dihydro-2H-1-benzopyran-3-yl)-4 -morpholinobenzamide for treatment of mood/anxiety/eating disorders
05/29/2003US20030100548 Antiarthritic agents; atherosclerosis and chronic obstructive pulmonary disease treatments
05/29/2003US20030100542 5-hydroxysapogenin derivatives with anti-dementia activity
05/29/2003US20030100536 Treating a herpes virus, atherosclerosis or restenosis
05/29/2003US20030100535 Administering a compound which binds to a galectin
05/29/2003US20030100515 Benzophenone glycopyranosides, preparation and therapeutic use
05/29/2003US20030100510 Crystallized structure of type IV collagen NC1 domain hexamer
1 ... 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 ... 1595